Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Accumulated Depreciation & AmortizationDepreciation & Amortization (IS)EBIATLeasesMachine, Furnitures, Fixtures & OtherOther Gross PP&E AdjustmentsProperty, Plant & Equipment (Gross)Shares IssuedShares OutstandingShares Repurchased
Ratios

Xeris Biopharma Holdings (XERS) Long-Term Debt Repayments (2022)

Historic Long-Term Debt Repayments for Xeris Biopharma Holdings (XERS) over the last 1 years, with Q1 2022 value amounting to $43.5 million.

  • Xeris Biopharma Holdings' Long-Term Debt Repayments changed N/A to $43.5 million in Q1 2022 from the same period last year, while for Dec 2022 it was $43.5 million, marking a year-over-year change of. This contributed to the annual value of $43.5 million for FY2022, which is N/A changed from last year.
  • Per Xeris Biopharma Holdings' latest filing, its Long-Term Debt Repayments stood at $43.5 million for Q1 2022.
  • In the past 5 years, Xeris Biopharma Holdings' Long-Term Debt Repayments registered a high of $43.5 million during Q1 2022, and its lowest value of $43.5 million during Q1 2022.